ArticlePLoS medicine2019
Cost-effectiveness of financial incentives for improving diet and health through Medicare and Medicaid: A microsimulation study.
Article in PLoS medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prospects of Food Taxes for Planetary Health: A Systematic Review of Modeling Studies.Nutrition reviews · 2025Pooled it
- The effect of food prescription programs on chronic disease management in primarily low-income populations: A systematic review and meta-analysis.Nutrition and health · 2022Pooled it
- Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019.Arquivos brasileiros de cardiologia · 2019Guideline
- Food Rx + CHW: a community health worker-led medically tailored grocery intervention to address food insecurity and type 2 diabetes, a pilot randomized trial.BMC public health · 2026Trial
- Plant-based diet in hyperkalemic chronic kidney disease patients receiving sodium zirconium cyclosilicate: a feasibility clinical trial.The American journal of clinical nutrition · 2024Trial
- Effect of Personalized Incentives on Dietary Quality of Groceries Purchased: A Randomized Crossover Trial.JAMA network open · 2021Trial
- Cost-effectiveness of financial incentives to improve glycemic control in adults with diabetes: A pilot randomized controlled trial.PloS one · 2021Trial
- Daily almond consumption in cardiovascular disease prevention via LDL-C change in the U.S. population: a cost-effectiveness analysis.BMC public health · 2020Trial
- Health Center-Based Community-Supported Agriculture: An RCT.American journal of preventive medicine · 2019Trial
- What Should Patients With Age-Related Macular Degeneration Eat?American journal of ophthalmology · 2026Review
- Alcohol-Mediated Skeletal Muscle Adaptations and Their Impact on Comorbidities.The American journal of pathology · 2026Review
- Economic Impact of a Precision Nutrition Digital Therapeutic on Employer Health Costs: A Multi-Employer and Multi-Year Claims Analysis.Healthcare (Basel, Switzerland) · 2025Article
- Evaluation of a State-Level Incentive Program to Improve Diet.JAMA network open · 2025Article
- The Delaware Food Farmacy: Integrating Medically Tailored Groceries and Community Health Workers into Chronic Disease Management.Delaware journal of public health · 2025Article
- Simulation of the fruit and vegetable intakes meeting the dietary reference intakes of Japanese adults from the National Health and Nutrition Survey.Scientific reports · 2025Article
- Perspective: Food Environment, Climate Change, Inflammation, Diet, and Health.Advances in nutrition (Bethesda, Md.) · 2025Review
- Will a Programmatic Framework Integrating Food Is Medicine Achieve Value on Investment?Journal of general internal medicine · 2025Article
- A Culinary-Based Intensive Lifestyle Program for Patients with Obesity: The Teaching Kitchen Collaborative Curriculum (TKCC) Pilot Study.Nutrients · 2025Article
- The realities of data derived from electronic health records to evaluate health outcomes, utilization, and cost of produce prescription programs: A multiple case study evaluation.Journal of public health research · 2025Article
- Astaxanthin in cancer therapy and prevention (Review).Biomedical reports · 2025Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundEconomic incentives through health insurance may promote healthier behaviors. Little is known about health and economic impacts of incentivizing diet, a leading risk factor for diabetes and cardiovascular disease (CVD), through Medicare and Medicaid. METHODS AND
findingsA validated microsimulation model (CVD-PREDICT) estimated CVD and diabetes cases prevented, quality-adjusted life years (QALYs), health-related costs (formal healthcare, informal healthcare, and lost-productivity costs), and incremental cost-effectiveness ratios (ICERs) of two policy scenarios for adults within Medicare and Medicaid, compared to a base case of no new intervention: (1) 30% subsidy on fruits and vegetables ("F&V incentive") and (2) 30% subsidy on broader healthful foods including F&V, whole grains, nuts/seeds, seafood, and plant oils ("healthy food incentive"). Inputs included national demographic and dietary data from the National Health and Nutrition Examination Survey (NHANES) 2009-2014, policy effects and diet-disease effects from meta-analyses, and policy and health-related costs from established sources. Overall, 82 million adults (35-80 years old) were on Medicare and/or Medicaid. The mean (SD) age was 68.1 (11.4) years, 56.2% were female, and 25.5% were non-whites. Health and cost impacts were simulated over the lifetime of current Medicare and Medicaid participants (average simulated years = 18.3 years). The F&V incentive was estimated to prevent 1.93 million CVD events, gain 4.64 million QALYs, and save $39.7 billion in formal healthcare costs. For the healthy food incentive, corresponding gains were 3.28 million CVD and 0.12 million diabetes cases prevented, 8.40 million QALYs gained, and $100.2 billion in formal healthcare costs saved, respectively. From a healthcare perspective, both scenarios were cost-effective at 5 years and beyond, with lifetime ICERs of $18,184/QALY (F&V incentive) and $13,194/QALY (healthy food incentive). From a societal perspective including informal healthcare costs and lost productivity, respective ICERs were $14,576/QALY and $9,497/QALY. Results were robust in probabilistic sensitivity analyses and a range of one-way sensitivity and subgroup analyses, including by different durations of the intervention (5, 10, and 20 years and lifetime), food subsidy levels (20%, 50%), insurance groups (Medicare, Medicaid, and dual-eligible), and beneficiary characteristics within each insurance group (age, race/ethnicity, education, income, and Supplemental Nutrition Assistant Program [SNAP] status). Simulation studies such as this one provide quantitative estimates of benefits and uncertainty but cannot directly prove health and economic impacts.
conclusionsEconomic incentives for healthier foods through Medicare and Medicaid could generate substantial health gains and be highly cost-effective.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.